GEP analysis suggested both positive and negative regulation of TCR/BCR in CD5+ DLBCL patients, and differential regulation of BCR downstream pathways (activation of NF-κB, MAPK, and Wnt pathways and inhibition of calcium influx). The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.